Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

.2013 Sep 27;288(39):27960-71.
doi: 10.1074/jbc.M113.485979. Epub 2013 Aug 2.

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases

Affiliations

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases

David E Ehmann et al. J Biol Chem..

Abstract

Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 10(1) m(-1)s(-1) for OXA-10 to 1.0 × 10(5) for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.

Keywords: Antibiotics; Drug Discovery; Enzyme Inhibitors; Enzyme Kinetics; Mass Spectrometry (MS).

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Structures of avibactam (1), avibactam13C-labeled in the urea (2), and avibactam13C-labeled at five carbon positions and15N labeled at the N1 position (3).
FIGURE 2.
FIGURE 2.
A, acylation (left) and deacylation (right) time courses for avibactam reacting with OXA-10.B, acyl enzyme exchange from acyl-OXA-10 to TEM-1.Top, ESI-MS spectrum of acyl-OXA-10 incubated with TEM-1 for 25 h without bicarbonate. The appearance of acyl-TEM-1 in this spectrum may result from free avibactam present in the acyl-OXA-10 sample.Bottom, ESI-MS spectrum of acyl-OXA-10 incubated with TEM-1 for 25 h in the presence of 10 mm sodium bicarbonate.
FIGURE 3.
FIGURE 3.
Time course of deacylation from KPC-2 followed by ESI-MS.A, excerpted time points displaying conversion of acyl-KPC-2 to unacylated KPC-2 and appearance of acyl-98 and acyl-79 peaks.B, plot of the relative fractions of KPC-2 and the three acylated forms over 32 h of incubation at 37 °C.
FIGURE 4.
FIGURE 4.
Structures of acyl enzyme intermediates and avibactam modifications based on the species seen in the deacylation time course. The mass of enzyme (A) is increased by 264 Da upon acylation by avibactam (B). Hydrolytic loss of SO3 would produce the hydroxylamine and acyl-80 species (C) from which loss of water would produce the imine and acyl-98 species (D). Imine hydrolysis would produce the carbonyl and acyl-97 species (E). Hydrolysis of the carbamate linkage and subsequent decarboxylation would regenerate enzymeA and produce compound4.
FIGURE 5.
FIGURE 5.
13C chemical shifts observed upon incubation of [13C]urea avibactam (compound 2) with KPC-2 at 37 °C. The 0 h spectrum was taken before the addition of KPC-2. Chemical shifts from peaks at excerpted time points are shown in Table 5.
FIGURE 6.
FIGURE 6.
Possible mechanisms for avibactam deacylation from KPC-2. The protein environment of acylated avibactam is based on the class A CTX-M-15 x-ray structure (PDB code 4HBU).A, the proposed ring-closing deacylation reaction to re-form intact avibactam in class A enzymes.B, proposed mechanism for sulfactam hydrolysis to produce the hydroxylamine avibactam fragment.C, proposed direct β-elimination of sulfate to produce the imine avibactam fragment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shahid M., Sobia F., Singh A., Malik A., Khan H. M., Jonas D., Hawkey P. M. (2009) β-Lactams and β-lactamase-inhibitors in current or potential clinical practice. A comprehensive update. Crit. Rev. Microbiol. 35, 81–108 - PubMed
    1. Bebrone C., Lassaux P., Vercheval L., Sohier J. S., Jehaes A., Sauvage E., Galleni M. (2010) Current challenges in antimicrobial chemotherapy. Focus on β-lactamase inhibition. Drugs 70, 651–679 - PubMed
    1. Drawz S. M., Bonomo R. A. (2010) Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160–201 - PMC - PubMed
    1. Bush K., Fisher J. F. (2011) Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Annu. Rev. Microbiol. 65, 455–478 - PubMed
    1. Bush K., Jacoby G. A. (2010) Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54, 969–976 - PMC - PubMed

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp